Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I

M. Al-Dhalimy, K. Overturf, M. Finegold, Markus Grompe

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

In human patients with hereditary tyrosinemia type I (HT1) a combination therapy of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3 cyclohexane dione (NTBC) and dietary restriction of phenylalanine and tyrosine is currently widely used. We previously reported that the use of NTBC in a murine model of HT1 abolished acute liver failure but did not prevent the development of hepatocellular carcinoma (HCC) in the setting of nonrestricted protein intake. Here we present the results obtained with higher doses of NTBC plus dietary tyrosine restriction on long-term follow up (>2 years). Liver function tests and succinylacetone levels were completely corrected with this regimen and cancer-free survival was improved when compared to historical controls. However, while no HT1 animals had HCC at age 13 months, the incidence was 2/16 (13%) at age 18 months and 1/6 (17%) after 24 months. Thus, even the most stringent therapy could not prevent the emergence of HCC in the mouse model of HT1, even when initiated prenatally.

Original languageEnglish (US)
Pages (from-to)38-45
Number of pages8
JournalMolecular Genetics and Metabolism
Volume75
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Tyrosinemias
Nutrition
Liver
Tyrosine
Hepatocellular Carcinoma
Diet
Phenylalanine
Animals
Acute Liver Failure
Liver Function Tests
Therapeutics
Proteins
Survival
Incidence
Neoplasms

Keywords

  • Hepatocarcinoma
  • Hereditary tyrosinemia
  • Liver disease
  • Treatment
  • Tyrosine

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Endocrinology, Diabetes and Metabolism

Cite this

Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. / Al-Dhalimy, M.; Overturf, K.; Finegold, M.; Grompe, Markus.

In: Molecular Genetics and Metabolism, Vol. 75, No. 1, 2002, p. 38-45.

Research output: Contribution to journalArticle

@article{f6357ba6f825498597bb8becd968bbbe,
title = "Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I",
abstract = "In human patients with hereditary tyrosinemia type I (HT1) a combination therapy of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3 cyclohexane dione (NTBC) and dietary restriction of phenylalanine and tyrosine is currently widely used. We previously reported that the use of NTBC in a murine model of HT1 abolished acute liver failure but did not prevent the development of hepatocellular carcinoma (HCC) in the setting of nonrestricted protein intake. Here we present the results obtained with higher doses of NTBC plus dietary tyrosine restriction on long-term follow up (>2 years). Liver function tests and succinylacetone levels were completely corrected with this regimen and cancer-free survival was improved when compared to historical controls. However, while no HT1 animals had HCC at age 13 months, the incidence was 2/16 (13{\%}) at age 18 months and 1/6 (17{\%}) after 24 months. Thus, even the most stringent therapy could not prevent the emergence of HCC in the mouse model of HT1, even when initiated prenatally.",
keywords = "Hepatocarcinoma, Hereditary tyrosinemia, Liver disease, Treatment, Tyrosine",
author = "M. Al-Dhalimy and K. Overturf and M. Finegold and Markus Grompe",
year = "2002",
doi = "10.1006/mgme.2001.3266",
language = "English (US)",
volume = "75",
pages = "38--45",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I

AU - Al-Dhalimy, M.

AU - Overturf, K.

AU - Finegold, M.

AU - Grompe, Markus

PY - 2002

Y1 - 2002

N2 - In human patients with hereditary tyrosinemia type I (HT1) a combination therapy of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3 cyclohexane dione (NTBC) and dietary restriction of phenylalanine and tyrosine is currently widely used. We previously reported that the use of NTBC in a murine model of HT1 abolished acute liver failure but did not prevent the development of hepatocellular carcinoma (HCC) in the setting of nonrestricted protein intake. Here we present the results obtained with higher doses of NTBC plus dietary tyrosine restriction on long-term follow up (>2 years). Liver function tests and succinylacetone levels were completely corrected with this regimen and cancer-free survival was improved when compared to historical controls. However, while no HT1 animals had HCC at age 13 months, the incidence was 2/16 (13%) at age 18 months and 1/6 (17%) after 24 months. Thus, even the most stringent therapy could not prevent the emergence of HCC in the mouse model of HT1, even when initiated prenatally.

AB - In human patients with hereditary tyrosinemia type I (HT1) a combination therapy of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3 cyclohexane dione (NTBC) and dietary restriction of phenylalanine and tyrosine is currently widely used. We previously reported that the use of NTBC in a murine model of HT1 abolished acute liver failure but did not prevent the development of hepatocellular carcinoma (HCC) in the setting of nonrestricted protein intake. Here we present the results obtained with higher doses of NTBC plus dietary tyrosine restriction on long-term follow up (>2 years). Liver function tests and succinylacetone levels were completely corrected with this regimen and cancer-free survival was improved when compared to historical controls. However, while no HT1 animals had HCC at age 13 months, the incidence was 2/16 (13%) at age 18 months and 1/6 (17%) after 24 months. Thus, even the most stringent therapy could not prevent the emergence of HCC in the mouse model of HT1, even when initiated prenatally.

KW - Hepatocarcinoma

KW - Hereditary tyrosinemia

KW - Liver disease

KW - Treatment

KW - Tyrosine

UR - http://www.scopus.com/inward/record.url?scp=0036352728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036352728&partnerID=8YFLogxK

U2 - 10.1006/mgme.2001.3266

DO - 10.1006/mgme.2001.3266

M3 - Article

C2 - 11825062

AN - SCOPUS:0036352728

VL - 75

SP - 38

EP - 45

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 1

ER -